Propanc Biopharma, Inc. (PPCBD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Camberwell, VIC, オーストラリア. 現CEOは James Nathanielsz.
PPCBD を有する IPO日 2012-11-12, 1 名の正社員, に上場 Other OTC, 時価総額 $87.31K.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
